Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Lifetime Prevalence of Cervical Cancer Screening in 55 Low-And Middle-Income Countries Publisher Pubmed



Lemp JM1 ; De Neve JW1 ; Bussmann H2 ; Chen S1, 3 ; Mannegoehler J4, 5 ; Theilmann M1 ; Marcus ME6 ; Ebert C7 ; Probst C1, 8 ; Tsabedzesibanyoni L9 ; Sturua L10 ; Kibachio JM11, 12 ; Moghaddam SS13 ; Martins JS14 Show All Authors
Authors
  1. Lemp JM1
  2. De Neve JW1
  3. Bussmann H2
  4. Chen S1, 3
  5. Mannegoehler J4, 5
  6. Theilmann M1
  7. Marcus ME6
  8. Ebert C7
  9. Probst C1, 8
  10. Tsabedzesibanyoni L9
  11. Sturua L10
  12. Kibachio JM11, 12
  13. Moghaddam SS13
  14. Martins JS14
  15. Houinato D15
  16. Houehanou C15
  17. Gurung MS16
  18. Gathecha G11
  19. Farzadfar F17
  20. Drydenpeterson S4, 18
  21. Davies JI19, 20
  22. Atun R21, 22
  23. Vollmer S6
  24. Barnighausen T1, 21, 23
  25. Geldsetzer P1, 24
Show Affiliations
Authors Affiliations
  1. 1. Heidelberg Institute of Global Health (HIGH), Medical Faculty and University Hospital, University of Heidelberg, Heidelberg, Germany
  2. 2. Department of Applied Tumor Biology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
  3. 3. Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
  4. 4. Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  5. 5. Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, United States
  6. 6. Department of Economics and Centre for Modern Indian Studies, University of Goettingen, Gottingen, Germany
  7. 7. RWI-Leibniz Institute for Economic Research, Essen (Berlin office), Germany
  8. 8. Institute for Mental Health Policy Research, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada
  9. 9. Eswatini Ministry of Health, Mbabane, Swaziland
  10. 10. Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia
  11. 11. Division of Non-Communicable Diseases, Kenya Ministry of Health, Nairobi, Kenya
  12. 12. Institute of Global Health, Faculty of Medicine, University of Geneva (UNIGE), Geneva, Switzerland
  13. 13. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  14. 14. Faculty of Medicine and Health Sciences, Universidade Nacional Timor Lorosa, Rua Jacinto Candido, Dili, Timor-Leste
  15. 15. Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin
  16. 16. Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan
  17. 17. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  18. 18. Botswana Harvard Aids Institute, Gaborone, Botswana
  19. 19. MRC/Wits Rural Public Health and Health Transitions Research Unit, University of Witwatersrand, School of Public Health, Johannesburg, South Africa
  20. 20. Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom
  21. 21. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, United States
  22. 22. Department of Global Health, Social Medicine, Harvard Medical School, Boston, MA, United States
  23. 23. Africa Health Research Institute, Somkhele, South Africa
  24. 24. Division of Primary Care and Population Health, Department of Medicine, Stanford University, 1265 Welch Rd, Stanford, 94305, CA, United States

Source: JAMA - Journal of the American Medical Association Published:2020


Abstract

Importance: The World Health Organization is developing a global strategy to eliminate cervical cancer, with goals for screening prevalence among women aged 30 through 49 years. However, evidence on prevalence levels of cervical cancer screening in low-and middle-income countries (LMICs) is sparse. Objective: To determine lifetime cervical cancer screening prevalence in LMICs and its variation across and within world regions and countries. Design, Setting, and Participants: Analysis of cross-sectional nationally representative household surveys carried out in 55 LMICs from 2005 through 2018. The median response rate across surveys was 93.8% (range, 64.0%-99.3%). The population-based sample consisted of 1136289 women aged 15 years or older, of whom 6885 (0.6%) had missing information for the survey question on cervical cancer screening. Exposures: World region, country; countries' economic, social, and health system characteristics; and individuals' sociodemographic characteristics. Main Outcomes and Measures: Self-report of having ever had a screening test for cervical cancer. Results: Of the 1129404 women included in the analysis, 542475 were aged 30 through 49 years. A country-level median of 43.6% (interquartile range [IQR], 13.9%-77.3%; range, 0.3%-97.4%) of women aged 30 through 49 years self-reported to have ever been screened, with countries in Latin America and the Caribbean having the highest prevalence (country-level median, 84.6%; IQR, 65.7%-91.1%; range, 11.7%-97.4%) and those in sub-Saharan Africa the lowest prevalence (country-level median, 16.9%; IQR, 3.7%-31.0%; range, 0.9%-50.8%). There was large variation in the self-reported lifetime prevalence of cervical cancer screening among countries within regions and among countries with similar levels of per capita gross domestic product and total health expenditure. Within countries, women who lived in rural areas, had low educational attainment, or had low household wealth were generally least likely to self-report ever having been screened. Conclusions and Relevance: In this cross-sectional study of data collected in 55 low-and middle-income countries from 2005 through 2018, there was wide variation between countries in the self-reported lifetime prevalence of cervical cancer screening. However, the median prevalence was only 44%, supporting the need to increase the rate of screening. © 2020 American Medical Association. All rights reserved.
Experts (# of related papers)